Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ventana rejects Roche takeover bid

This article was originally published in The Gray Sheet

Executive Summary

Tissue-based diagnostics firm Ventana rejects Roche's $3 billion hostile takeover bid as "inadequate" July 11. Roche, which hopes to pair the technology with its targeted cancer drugs for advanced personalized medicine, had announced the offer June 25. The diversified drug and diagnostics giant responded to Ventana's dismissal of the offer in a same-day letter, stating that if there is "additional information that would support a valuation in excess of our offer, we would be willing to consider it in a negotiation." Roche adds that if a negotiated transaction is not possible, it will continue with its $75-per-share cash tender offer, launched June 27, and consider taking the issue directly to Ventana's shareholders at the firm's 2008 annual meeting. "Such action may include the nomination of new directors to Ventana's board and/or proposals to amend Ventana's bylaws," Roche says (1"The Gray Sheet" July 2, 2007, p. 10)...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT025034

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel